GENELANCET BIOSCIENCES INC

Burlingame, CA · Biotech · Private

CRISPR-Cas9 scar-less base editor technology to permanently inactivate hepatitis B virus cccDNA and integrated DNA

genelancetbio.com →
Grants
$300K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of STAR Editors (CRISPR-Cas9/lgRNA-ssDNA) for the cure of chronic hepatitis B$300,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1923Immunocore——
1924MOGLING BIO INC——
1925Arch Innotek, LLC——
1926GENELANCET BIOSCIENCES INC——
1927CODA Biotherapeutics, Inc.——
1928MOLECULAR EXPRESS, INC.——
1929Surf Air Global Ltd—$9.9M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.